CN108699078A - 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法 - Google Patents
噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法 Download PDFInfo
- Publication number
- CN108699078A CN108699078A CN201780014543.0A CN201780014543A CN108699078A CN 108699078 A CN108699078 A CN 108699078A CN 201780014543 A CN201780014543 A CN 201780014543A CN 108699078 A CN108699078 A CN 108699078A
- Authority
- CN
- China
- Prior art keywords
- compound
- group
- inhibitors
- diffraction pattern
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(C)(C(O)=O)N(C(N(CCc1ccccc1OC)c1c2c(C)c(-c3ncc[o]3)[s]1)=*OC1CCOCC1)C2=O Chemical compound CC(C)(C(O)=O)N(C(N(CCc1ccccc1OC)c1c2c(C)c(-c3ncc[o]3)[s]1)=*OC1CCOCC1)C2=O 0.000 description 8
- DBNLRXIWDMHQDJ-AWEZNQCLSA-N COc1ccccc1[C@H](CO)OC1CCOCC1 Chemical compound COc1ccccc1[C@H](CO)OC1CCOCC1 DBNLRXIWDMHQDJ-AWEZNQCLSA-N 0.000 description 2
- KDRXNKFADSHNQT-UHFFFAOYSA-N CC(C)(C(O)=O)N(C(c1c(N2CCc3c(C(COCC4)C4O)cccc3OC)[s]c(-c3ncc[o]3)c1C)=O)C2=O Chemical compound CC(C)(C(O)=O)N(C(c1c(N2CCc3c(C(COCC4)C4O)cccc3OC)[s]c(-c3ncc[o]3)c1C)=O)C2=O KDRXNKFADSHNQT-UHFFFAOYSA-N 0.000 description 1
- MZGPVRLFQHABKR-UHFFFAOYSA-N CC(C)(C)OC(C(C)(C)CN(C(C(C(N1)S2)C(C)=C2Br)=O)C1=O)=O Chemical compound CC(C)(C)OC(C(C)(C)CN(C(C(C(N1)S2)C(C)=C2Br)=O)C1=O)=O MZGPVRLFQHABKR-UHFFFAOYSA-N 0.000 description 1
- NFBQJHOKTSYEDJ-QHCPKHFHSA-N CC(C)(C)OC(C(C)(C)N(C(c1c(N2C[C@@H](c3ccccc3OC)OC3CCOCC3)[s]c(-c3ncc[o]3)c1C)=O)C2=O)=O Chemical compound CC(C)(C)OC(C(C)(C)N(C(c1c(N2C[C@@H](c3ccccc3OC)OC3CCOCC3)[s]c(-c3ncc[o]3)c1C)=O)C2=O)=O NFBQJHOKTSYEDJ-QHCPKHFHSA-N 0.000 description 1
- RTPMRBJFFOEEER-PEHNNWDASA-N CC(c1c(C)c([C@H]2OC2N(C(C)(C)C(O)=O)C(N2CCC3C(C(COCC4)C4O)=CC=CC3OC)=O)c2[s]1)O/C=C\N Chemical compound CC(c1c(C)c([C@H]2OC2N(C(C)(C)C(O)=O)C(N2CCC3C(C(COCC4)C4O)=CC=CC3OC)=O)c2[s]1)O/C=C\N RTPMRBJFFOEEER-PEHNNWDASA-N 0.000 description 1
- UXDCKEUBQDLBCD-UHFFFAOYSA-N CCC(C)(C(OC(C)(C)C)=O)N(C(Cc1c(N2CCC3C=CC=CC3OCC)[s]c(-c3ncc[o]3)c1C)=O)C2=O Chemical compound CCC(C)(C(OC(C)(C)C)=O)N(C(Cc1c(N2CCC3C=CC=CC3OCC)[s]c(-c3ncc[o]3)c1C)=O)C2=O UXDCKEUBQDLBCD-UHFFFAOYSA-N 0.000 description 1
- SROHXGIULJMAEK-UHFFFAOYSA-N COc1cccc(C(COCC2)C2O)c1CCO Chemical compound COc1cccc(C(COCC2)C2O)c1CCO SROHXGIULJMAEK-UHFFFAOYSA-N 0.000 description 1
- URENTZAFECEONT-AWEZNQCLSA-N COc1ccccc1[C@H](CBr)OC1CCOCC1 Chemical compound COc1ccccc1[C@H](CBr)OC1CCOCC1 URENTZAFECEONT-AWEZNQCLSA-N 0.000 description 1
- RLEMZTSNMGFANA-HNNXBMFYSA-N COc1ccccc1[C@H](COS(C)(=O)=O)OC1CCOCC1 Chemical compound COc1ccccc1[C@H](COS(C)(=O)=O)OC1CCOCC1 RLEMZTSNMGFANA-HNNXBMFYSA-N 0.000 description 1
- GVJJJWGPFOUYND-UHFFFAOYSA-N OC1=SCOCC1 Chemical compound OC1=SCOCC1 GVJJJWGPFOUYND-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/001—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by metabolizing one of the enantiomers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Physics & Mathematics (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110182955.3A CN112920200A (zh) | 2016-03-02 | 2017-03-01 | 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法 |
| CN202411834934.5A CN119977993A (zh) | 2016-03-02 | 2017-03-01 | 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662302755P | 2016-03-02 | 2016-03-02 | |
| US62/302,755 | 2016-03-02 | ||
| US201662303237P | 2016-03-03 | 2016-03-03 | |
| US62/303,237 | 2016-03-03 | ||
| PCT/US2017/020271 WO2017151816A1 (en) | 2016-03-02 | 2017-03-01 | Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110182955.3A Division CN112920200A (zh) | 2016-03-02 | 2017-03-01 | 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法 |
| CN202411834934.5A Division CN119977993A (zh) | 2016-03-02 | 2017-03-01 | 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108699078A true CN108699078A (zh) | 2018-10-23 |
Family
ID=58347936
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780014543.0A Pending CN108699078A (zh) | 2016-03-02 | 2017-03-01 | 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法 |
| CN202411834934.5A Pending CN119977993A (zh) | 2016-03-02 | 2017-03-01 | 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法 |
| CN202110182955.3A Pending CN112920200A (zh) | 2016-03-02 | 2017-03-01 | 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411834934.5A Pending CN119977993A (zh) | 2016-03-02 | 2017-03-01 | 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法 |
| CN202110182955.3A Pending CN112920200A (zh) | 2016-03-02 | 2017-03-01 | 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10183951B2 (enExample) |
| EP (2) | EP4364795A3 (enExample) |
| JP (3) | JP6944462B2 (enExample) |
| KR (3) | KR102700008B1 (enExample) |
| CN (3) | CN108699078A (enExample) |
| AU (3) | AU2017226267B2 (enExample) |
| BR (1) | BR112018067408A2 (enExample) |
| CA (4) | CA3155220C (enExample) |
| ES (1) | ES2972487T3 (enExample) |
| IL (1) | IL261255A (enExample) |
| MX (1) | MX2018010427A (enExample) |
| PL (1) | PL3423456T3 (enExample) |
| SG (1) | SG11201807077RA (enExample) |
| TW (3) | TWI818828B (enExample) |
| WO (1) | WO2017151816A1 (enExample) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109810085A (zh) * | 2019-04-19 | 2019-05-28 | 上海皓元生物医药科技有限公司 | Acc抑制剂及其中间体的制备方法 |
| CN112574253A (zh) * | 2019-09-29 | 2021-03-30 | 上海喀露蓝科技有限公司 | 磷酸或磷酸酯类衍生物、其制备方法及其在医药上的用途 |
| CN112778325A (zh) * | 2019-11-07 | 2021-05-11 | 南京瑞捷医药科技有限公司 | 一种acc抑制剂及其用途 |
| WO2021110138A1 (zh) * | 2019-12-05 | 2021-06-10 | 漳州片仔癀药业股份有限公司 | 噻吩并[2,3-c]哒嗪-4(1H)-酮类化合物的晶型及其制备方法和应用 |
| WO2021110135A1 (zh) * | 2019-12-05 | 2021-06-10 | 漳州片仔癀药业股份有限公司 | 作为acc1和acc2抑制剂的晶型及其制备方法和应用 |
| CN117529320A (zh) * | 2021-02-22 | 2024-02-06 | 格雷威顿生物科技有限公司 | 用于治疗病毒感染的rock2抑制剂 |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI625121B (zh) | 2009-07-13 | 2018-06-01 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| MX370976B (es) | 2011-11-11 | 2020-01-10 | Gilead Apollo Llc | Inhibidores de acetil coa carboxilasa (acc) y usos de los mismos. |
| ES2734713T3 (es) | 2015-07-06 | 2019-12-11 | Gilead Sciences Inc | Moduladores Cot y métodos de utilización de los mismos |
| AR106472A1 (es) | 2015-10-26 | 2018-01-17 | Gilead Apollo Llc | Inhibidores de acc y usos de los mismos |
| EP3380478B1 (en) | 2015-11-25 | 2020-12-23 | Gilead Apollo, LLC | Ester acc inhibitors and uses thereof |
| US20170166582A1 (en) | 2015-11-25 | 2017-06-15 | Gilead Apollo, Llc | Pyrazole acc inhibitors and uses thereof |
| CN108347939B (zh) | 2015-11-25 | 2021-09-28 | 吉利德阿波罗公司 | 含有2,4-二氧代-1,4-二氢噻吩并[2,3-d]嘧啶的衍生物的杀真菌组合物 |
| CA3155220C (en) | 2016-03-02 | 2024-01-16 | Gilead Apollo, Llc | Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof |
| CA3137479A1 (en) | 2017-03-03 | 2018-09-07 | Gilead Sciences, Inc. | Processes for preparing acc inhibitors and solid forms thereof |
| ES2982801T3 (es) | 2017-03-28 | 2024-10-17 | Gilead Sciences Inc | Combinaciones terapéuticas para el tratamiento de las enfermedades hepáticas |
| WO2019015583A1 (en) * | 2017-07-17 | 2019-01-24 | Nanjing Ruijie Pharmatech Co., Ltd. | NOVEL COMPOUNDS AND THEIR USES AS ACC INHIBITORS |
| KR20190036705A (ko) * | 2017-09-28 | 2019-04-05 | 한미약품 주식회사 | (2r)-2-(2-메톡시페닐)-2-(옥산-4-일옥시)에탄-1-올 화합물의 신규 제조방법 및 이에 사용되는 중간체 |
| CN111182904A (zh) | 2017-10-06 | 2020-05-19 | 吉利德科学公司 | 包含acc抑制剂的组合治疗 |
| TWI915558B (zh) | 2019-06-14 | 2026-02-21 | 美商基利科學股份有限公司 | Cot 調節劑及其使用方法 |
| AR119594A1 (es) | 2019-08-09 | 2021-12-29 | Gilead Sciences Inc | Derivados de tienopirimidina como inhibidores acc y usos de los mismos |
| JP2022548617A (ja) | 2019-09-19 | 2022-11-21 | ノバルティス アーゲー | Ｆｘｒアゴニストを含む処置 |
| CN110746439B (zh) * | 2019-10-18 | 2020-10-30 | 南京瑞捷医药科技有限公司 | 一种噻吩并嘧啶二酮化合物的制备方法 |
| CN114728168B (zh) | 2019-11-15 | 2024-04-09 | 吉利德科学公司 | 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途 |
| CA3175541A1 (en) | 2020-03-30 | 2021-10-07 | Gilead Sciences, Inc. | Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound |
| EP4126862B1 (en) | 2020-04-02 | 2025-05-21 | Gilead Sciences, Inc. | Process for preparing a cot inhibitor compound |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| TWI843503B (zh) | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| US11702407B2 (en) | 2020-06-03 | 2023-07-18 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| EP4304711A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| ES3061522T3 (en) | 2021-03-29 | 2026-04-06 | Gilead Sciences Inc | Khk inhibitors |
| AU2022273631B2 (en) | 2021-05-11 | 2025-04-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| KR20240007233A (ko) | 2021-05-13 | 2024-01-16 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| TW202345826A (zh) | 2021-06-04 | 2023-12-01 | 美商基利科學股份有限公司 | 治療nash之方法 |
| TW202311256A (zh) | 2021-06-18 | 2023-03-16 | 美商基利科學股份有限公司 | 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑 |
| KR102337422B1 (ko) | 2021-07-27 | 2021-12-08 | (주)최금실 | 호호바오일을 포함하는 피부진정 및 트러블 개선용 화장료 조성물 및 이의 제조방법 |
| KR102309616B1 (ko) | 2021-07-27 | 2021-10-05 | 최금실 | 호호바오일을 포함하는 피부 재생 및 피부 보습용 화장료 조성물 및 이의 제조방법 |
| US11939318B2 (en) | 2021-12-08 | 2024-03-26 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| CN115785066B (zh) | 2022-12-08 | 2024-05-31 | 广东工业大学 | 曲格列汀晶型f及其制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104105485A (zh) * | 2011-11-11 | 2014-10-15 | 尼普斯阿波罗有限公司 | Acc抑制剂和其用途 |
| WO2015007451A1 (en) * | 2013-07-15 | 2015-01-22 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4670560A (en) | 1986-04-28 | 1987-06-02 | Ortho Pharmaceutical Corporation | Thienopyrimidine-2,4-dione derivatives and intermediates thereof |
| JPH02225485A (ja) | 1989-02-27 | 1990-09-07 | Taiho Yakuhin Kogyo Kk | チエノピリミジン―３―酢酸誘導体 |
| TW276256B (enExample) | 1993-08-26 | 1996-05-21 | Takeda Pharm Industry Co Ltd | |
| JP3811196B2 (ja) | 1993-08-26 | 2006-08-16 | 武田薬品工業株式会社 | エンドセリン拮抗剤、チエノピリミジン誘導体およびその製造法 |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| WO2000061583A1 (en) | 1995-06-07 | 2000-10-19 | Cell Therapeutics, Inc. | Xanthine derivatives and analogs as cell signaling inhibitors |
| JPH09110873A (ja) | 1995-08-17 | 1997-04-28 | Takeda Chem Ind Ltd | チエノピリミジン誘導体、その製造法および用途 |
| AU6670196A (en) | 1995-08-17 | 1997-03-12 | Takeda Chemical Industries Ltd. | Thienopyrimidine derivatives, their production and use |
| AU2407997A (en) | 1996-04-30 | 1997-11-19 | Takeda Chemical Industries Ltd. | Combined use of gnrh agonist and antagonist |
| JP2007302703A (ja) | 1996-04-30 | 2007-11-22 | Takeda Chem Ind Ltd | 医薬組成物 |
| US6984644B2 (en) | 1997-05-28 | 2006-01-10 | Astrazeneca Ab | Treatment of skin disorders using thieno[2,3-D]pyrimidinediones |
| SE9702001D0 (sv) | 1997-05-28 | 1997-05-28 | Astra Pharma Prod | Novel compounds |
| DE19754082A1 (de) | 1997-12-05 | 1999-06-10 | Knoll Ag | Methode zur Bekämpfung der Fettleibigkeit |
| MXPA03004926A (es) | 2001-02-14 | 2005-02-14 | Warner Lambert Co | Inhibidores de metaloproteinasas de matriz basados en pirimidinonas fusionadas. |
| US7655658B2 (en) | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
| WO2003072197A1 (en) | 2002-02-27 | 2003-09-04 | Pfizer Products Inc. | Acc inhibitors |
| AU2003253165A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
| ES2324472T3 (es) | 2003-01-06 | 2009-08-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Herbicidas que inhiben la accion de acetil-coa carboxilasa en vegetales para su uso como pesticidas. |
| CN101153042A (zh) | 2003-01-29 | 2008-04-02 | 武田药品工业株式会社 | 噻吩并嘧啶化合物及其用途 |
| WO2006014647A2 (en) | 2004-07-21 | 2006-02-09 | Athersys, Inc. | Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof |
| CA2644996A1 (en) | 2006-03-02 | 2007-09-13 | Cv Therapeutics, Inc. | A2a adenosine receptor antagonists |
| EP2151440A4 (en) | 2007-05-21 | 2010-10-20 | Takeda Pharmaceutical | Heterocyclic compound and use thereof |
| WO2009155611A1 (en) | 2008-06-20 | 2009-12-23 | Kinemed, Inc. | Compositions for the treatment of fibrotic diseases or conditions |
| JP5535931B2 (ja) | 2008-10-27 | 2014-07-02 | 武田薬品工業株式会社 | 二環性化合物 |
| US20100113473A1 (en) | 2008-10-30 | 2010-05-06 | Player Mark R | Aryl amide compound as an acetyl coenzyme a carboxylase inhibitor |
| PT2519527E (pt) | 2009-12-29 | 2014-02-17 | Poxel | Tieno[2,3-b]piridinodiona como activadores de ampk e suas utilizações terapêuticas |
| WO2012090219A2 (en) | 2010-12-31 | 2012-07-05 | Jubilant Biosys Ltd. | Thiazole compounds useful as acetyl-coa carboxylase (acc) inhibitors |
| WO2013123231A1 (en) | 2012-02-15 | 2013-08-22 | Robert Bosch Gmbh | Pressure sensor with doped electrode |
| JP5842804B2 (ja) * | 2012-12-28 | 2016-01-13 | カシオ計算機株式会社 | 表示端末装置及びプログラム |
| EP2994128B1 (en) | 2013-05-10 | 2019-01-30 | Gilead Apollo, LLC | Acc inhibitors and uses thereof |
| AU2014262636A1 (en) | 2013-05-10 | 2015-11-26 | Gilead Apollo, Llc | ACC inhibitors and uses thereof |
| MX2017008844A (es) | 2015-01-09 | 2018-03-14 | Gilead Apollo Llc | Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico. |
| AR106472A1 (es) * | 2015-10-26 | 2018-01-17 | Gilead Apollo Llc | Inhibidores de acc y usos de los mismos |
| PL3380479T3 (pl) * | 2015-11-25 | 2023-05-08 | Gilead Apollo, Llc | Triazolowe inhibitory acc i ich zastosowania |
| CN108347939B (zh) | 2015-11-25 | 2021-09-28 | 吉利德阿波罗公司 | 含有2,4-二氧代-1,4-二氢噻吩并[2,3-d]嘧啶的衍生物的杀真菌组合物 |
| EP3380478B1 (en) | 2015-11-25 | 2020-12-23 | Gilead Apollo, LLC | Ester acc inhibitors and uses thereof |
| US20170166582A1 (en) * | 2015-11-25 | 2017-06-15 | Gilead Apollo, Llc | Pyrazole acc inhibitors and uses thereof |
| CA3155220C (en) | 2016-03-02 | 2024-01-16 | Gilead Apollo, Llc | Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof |
| AU2018209006B2 (en) | 2017-01-22 | 2021-04-22 | Sunshine Lake Pharma Co., Ltd. | Thienopyrimidine derivative and use thereof in medicine |
| KR20190036705A (ko) | 2017-09-28 | 2019-04-05 | 한미약품 주식회사 | (2r)-2-(2-메톡시페닐)-2-(옥산-4-일옥시)에탄-1-올 화합물의 신규 제조방법 및 이에 사용되는 중간체 |
| US12323113B2 (en) | 2021-11-29 | 2025-06-03 | Macom Technology Solutions Holdings, Inc. | Circuit and method of shutdown for bias network in high voltage amplifier |
-
2017
- 2017-03-01 CA CA3155220A patent/CA3155220C/en active Active
- 2017-03-01 US US15/446,873 patent/US10183951B2/en active Active
- 2017-03-01 ES ES17711446T patent/ES2972487T3/es active Active
- 2017-03-01 WO PCT/US2017/020271 patent/WO2017151816A1/en not_active Ceased
- 2017-03-01 BR BR112018067408A patent/BR112018067408A2/pt not_active Application Discontinuation
- 2017-03-01 JP JP2018545600A patent/JP6944462B2/ja active Active
- 2017-03-01 CN CN201780014543.0A patent/CN108699078A/zh active Pending
- 2017-03-01 TW TW111147581A patent/TWI818828B/zh active
- 2017-03-01 TW TW106106735A patent/TWI788281B/zh active
- 2017-03-01 PL PL17711446.9T patent/PL3423456T3/pl unknown
- 2017-03-01 MX MX2018010427A patent/MX2018010427A/es unknown
- 2017-03-01 CA CA3015526A patent/CA3015526C/en active Active
- 2017-03-01 AU AU2017226267A patent/AU2017226267B2/en active Active
- 2017-03-01 CA CA3172549A patent/CA3172549C/en active Active
- 2017-03-01 TW TW112134636A patent/TWI844474B/zh active
- 2017-03-01 CN CN202411834934.5A patent/CN119977993A/zh active Pending
- 2017-03-01 SG SG11201807077RA patent/SG11201807077RA/en unknown
- 2017-03-01 CA CA3220447A patent/CA3220447C/en active Active
- 2017-03-01 EP EP23219327.6A patent/EP4364795A3/en active Pending
- 2017-03-01 KR KR1020237007117A patent/KR102700008B1/ko active Active
- 2017-03-01 EP EP17711446.9A patent/EP3423456B1/en active Active
- 2017-03-01 CN CN202110182955.3A patent/CN112920200A/zh active Pending
- 2017-03-01 KR KR1020247028256A patent/KR102744343B1/ko active Active
- 2017-03-01 KR KR1020187027295A patent/KR102622161B1/ko active Active
-
2018
- 2018-08-20 IL IL261255A patent/IL261255A/en unknown
- 2018-12-12 US US16/217,935 patent/US10487090B2/en active Active
-
2019
- 2019-10-10 US US16/598,411 patent/US11104687B2/en active Active
-
2021
- 2021-07-26 AU AU2021209149A patent/AU2021209149B2/en active Active
- 2021-08-03 US US17/393,030 patent/US11912718B2/en active Active
- 2021-09-10 JP JP2021147802A patent/JP7184988B2/ja active Active
-
2022
- 2022-11-24 JP JP2022187472A patent/JP7356564B2/ja active Active
-
2023
- 2023-07-18 AU AU2023206094A patent/AU2023206094B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104105485A (zh) * | 2011-11-11 | 2014-10-15 | 尼普斯阿波罗有限公司 | Acc抑制剂和其用途 |
| WO2015007451A1 (en) * | 2013-07-15 | 2015-01-22 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
Non-Patent Citations (6)
| Title |
|---|
| COLUMBUS, OHIO, US REGISTRY[ONLINE]: "STN检索报告", 《STN REGISTRY》 * |
| MICHAEL R. REEDER ET AL.: "An Improved Method for the Palladium Cross-Coupling Reaction of Oxazol-2-ylzinc Derivatives with Aryl Bromides", 《ORGANIC PROCESS RESEARCH & DEVELOPMENT》 * |
| QUELET,RAYMOND ET AL.: "Preparation of o-methoxystyrene;transformation into o-methoxyphenylacetylene", 《COMPT.REND.》 * |
| SHI-ZHENWANG ET AL.: "Separation of citalopram intermediate from its acetate by solvent extraction", 《SEPARATION AND PURIFICATION TECHNOLOGY》 * |
| SUJOY RANA ET AL.: "Catalytic Electrophilic Halogenations and Haloalkoxylations by Non-Heme Iron Halides", 《ADV. SYNTH. CATAL.》 * |
| 吕扬等: "《晶型药物》", 31 October 2009, 人民卫生出版社 * |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109810085A (zh) * | 2019-04-19 | 2019-05-28 | 上海皓元生物医药科技有限公司 | Acc抑制剂及其中间体的制备方法 |
| CN112574253A (zh) * | 2019-09-29 | 2021-03-30 | 上海喀露蓝科技有限公司 | 磷酸或磷酸酯类衍生物、其制备方法及其在医药上的用途 |
| CN112574253B (zh) * | 2019-09-29 | 2021-08-27 | 上海喀露蓝科技有限公司 | 磷酸或磷酸酯类衍生物、其制备方法及其在医药上的用途 |
| CN114599654B (zh) * | 2019-11-07 | 2023-07-04 | 南京瑞捷医药科技有限公司 | 一种acc抑制剂及其用途 |
| CN112778325A (zh) * | 2019-11-07 | 2021-05-11 | 南京瑞捷医药科技有限公司 | 一种acc抑制剂及其用途 |
| WO2021088980A1 (zh) * | 2019-11-07 | 2021-05-14 | 南京瑞捷医药科技有限公司 | 一种acc抑制剂及其用途 |
| US12384798B2 (en) | 2019-11-07 | 2025-08-12 | Nanjing Ruijie Pharma Co., Ltd | ACC inhibitor and use thereof |
| CN114599654A (zh) * | 2019-11-07 | 2022-06-07 | 南京瑞捷医药科技有限公司 | 一种acc抑制剂及其用途 |
| WO2021110138A1 (zh) * | 2019-12-05 | 2021-06-10 | 漳州片仔癀药业股份有限公司 | 噻吩并[2,3-c]哒嗪-4(1H)-酮类化合物的晶型及其制备方法和应用 |
| CN114787166A (zh) * | 2019-12-05 | 2022-07-22 | 漳州片仔癀药业股份有限公司 | 噻吩并[2,3-c]哒嗪-4(1H)-酮类化合物的晶型及其制备方法和应用 |
| US11578081B1 (en) | 2019-12-05 | 2023-02-14 | Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. | Crystal form as inhibitor of ACC1 and ACC2, and preparation method therefor and use thereof |
| US11673899B2 (en) | 2019-12-05 | 2023-06-13 | Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. | Crystal form of thieno[2,3-c]pyridazine-4(1H)-one compound, preparation method therefor and use thereof |
| CN114746426A (zh) * | 2019-12-05 | 2022-07-12 | 漳州片仔癀药业股份有限公司 | 作为acc1和acc2抑制剂的晶型及其制备方法和应用 |
| CN114787166B (zh) * | 2019-12-05 | 2023-09-19 | 漳州片仔癀药业股份有限公司 | 噻吩并[2,3-c]哒嗪-4(1H)-酮类化合物的晶型及其制备方法和应用 |
| CN114746426B (zh) * | 2019-12-05 | 2023-12-01 | 漳州片仔癀药业股份有限公司 | 作为acc1和acc2抑制剂的晶型及其制备方法和应用 |
| WO2021110135A1 (zh) * | 2019-12-05 | 2021-06-10 | 漳州片仔癀药业股份有限公司 | 作为acc1和acc2抑制剂的晶型及其制备方法和应用 |
| CN117529320A (zh) * | 2021-02-22 | 2024-02-06 | 格雷威顿生物科技有限公司 | 用于治疗病毒感染的rock2抑制剂 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7356564B2 (ja) | チエノピリミジンジオンａｃｃ阻害剤の固体形態およびその生成のための方法 | |
| HK40110261A (en) | Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof | |
| HK40055242A (en) | Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof | |
| HK40125827A (zh) | 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法 | |
| HK1262116A1 (en) | Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof | |
| HK40002905B (en) | Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof | |
| HK40002905A (en) | Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1262116 Country of ref document: HK |
|
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181023 |
|
| RJ01 | Rejection of invention patent application after publication |